WRAL Tech Wire

OxyBio gets more time to show it meets NASDAQ listing rules

The Nasdaq, which had sent Oxygen Biotherapeutics, a delisting notice in March, gives the company more time to show it meets listing requirements.

 OxyBio weighs options to move TBI drug through trials

Oxygen Biotherapeutics' (NASDAQ:OXBT) recent securities offering net $1.9 million -- enough to open clinical trial sites in Switzerland and Israel to study traumatic brain injury drug candidate Oxycyte. Beyond must take other financial steps.

 OxyBio to settle investors' suit for $600K

 OxyBio strikes supply, manufacturing deal for skin product

 Oxygen Biotherapeutics picks PPD to run clinical trial

Oxygen Biotherapeutics picks PPD as the contract research organization to run a Phase 2 clinical trial on a proposed treatment for traumatic brain injury.

 Oxygen Biotherapeutics is moving R&D lab to N.C.

The drug firm has closed a facility in California and says it is seeking lab space in the Triangle.

 Both revenue, loss rise at Oxygen Biotherapeutics

Oxygen Biotherapeutics reported this week a net loss of $15.7 million for its recently completed fiscal year, up from a net loss of $10.4 million a year ago. Total net revenue did rise, though, to nearly $364,000 from last year.

 RTP-based OxyBio terminates distribution agreements

Oxygen Biotherapeutics says it will focus on sales of its skin product in North Carolina and South Florida.

 Oxygen Biotherapeutics, partner to target strokes

In an ischemic stroke, a clot blocks a vessel to the brain and deprives it of oxygen. Stroke treatments aim to salvage as much of the surrounding, salvageable brain tissue as possible.

 Oxygen Biotherapeutics to raise $7.5M in private placement

The funding follows a shakeup at Oxygen's executive offices and board. Former Chairman and CEO Chris Stern's positions at the company were terminated in August following an internal investigation that concluded Stern lied about his academic background and conducted undisclosed securities deals that he tried to cover up. Shortly afterward, two members of Oxygen's board of directors resigned after shareholders withheld their votes for the two directors.

 Oxygen Biotherapeutics shakeup hits board of directors

Two board members resign in the wake of disclosures of alleged improprieties leading to the ouster of former CEO Chris Stern.

 Oxygen Biotherapeutics fires top executive 'for cause'

The Morrisville-based developer of oxygen-based health products dismisses Chairman and CEO Chris Stern after audit investigation.

 Oxygen Biotherapeutics teams with Scottish firm for R&D

The two firms plan to partner on preclinical research into combating strokes.

 Oxygen Biotherapeutics secures $245,000 in federal grants for brain injury drug

The Durham-based drug development firm is developing a treatment targeting brain and spinal cord injuries.

 Oxygen Biotherapeutics to raise $75M in stock offering

In SEC filing, the Durham-based firm says it also is seeking other financing and alliances. OxyBio also begins distribution of a new over-the-counter skin care product.